<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194479</url>
  </required_header>
  <id_info>
    <org_study_id>HIC1005006832</org_study_id>
    <secondary_id>R37-20495</secondary_id>
    <nct_id>NCT01194479</nct_id>
  </id_info>
  <brief_title>Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.</brief_title>
  <official_title>The Effect of the Beta 2 Agonist, Formoterol, on Recovery From Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin treatment often causes the blood glucose levels to fall too low. The body usually
      responds to low blood glucose levels by releasing hormones which act against the insulin to
      help correct the low blood glucose levels. However, this hormone response can be altered in
      people with diabetes. Currently there are no therapeutic agents that can be used to improve
      the recovery from hypoglycemia (low blood sugar). The aim of this study is to determine
      whether a formoterol inhaler can be used to improve and accelerate the recovery from
      hypoglycemia in patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Note: Below is the original detailed description submitted in 2010. The recruitment for this
      study was stopped at 7 subjects in each study arm. The study design and outcome measures did
      not change for this study. See below for further details.

      Original: 15 subjects with well controlled type 1 diabetes and regular hypoglycemia and 15
      healthy volunteers will be recruited for this study.

      If you agree to participate in this study, you will be asked to participate in a screening at
      Yale New Haven Hospital. Each study subject will undergo two hypoglycemic clamp studies (a
      procedure where the blood sugar is closely regulated with intravenous insulin and glucose.)
      In these hypoglycemic clamp studies, the subject will be given an inhaler. On one visit the
      inhaler will contain formoterol capsules and on the other visit, the subject will be given
      'dummy' capsules. Subjects will be required to be admitted to the HRU the night before the
      study so that glucose levels can be stabilized and hypoglycemia avoided.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon (pg/mL)</measure>
    <time_frame>up to 120 minutes</time_frame>
    <description>Glucagon levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Epinephrine (pg/mL)</measure>
    <time_frame>up to 120 minutes</time_frame>
    <description>Epinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norepinephrine (pg/mL)</measure>
    <time_frame>up to 120 minutes</time_frame>
    <description>Norepinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Levels (Average)</measure>
    <time_frame>Up to 120 minutes</time_frame>
    <description>Blood glucose levels will be checked every 5 minutes during the 120 minute study session in order to maintain blood glucose levels in the normal and hypoglycemic range. Presented is the average of the collected values.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 1 Diabetics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The active group were participants with type 1 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol inhaler, 12mcg capsules, 4 capsules for one administration</description>
    <arm_group_label>Type 1 Diabetics</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <other_name>Foradil Aerolizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in both arms received placebo on 1 of the 2 visits.</description>
    <arm_group_label>Type 1 Diabetics</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk)

          -  age 18-50

          -  BMI 18-30

        Exclusion Criteria:

          -  pregnancy

          -  significant diabetes complications

          -  liver disease, cirrhosis

          -  cardiac disease

          -  neurological disorder

          -  autonomic neuropathy

          -  kidney disease

          -  lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sherwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Belfort-DeAguiar RD, Naik S, Hwang J, Szepietowska B, Sherwin RS. Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2015 Sep;38(9):1736-41. doi: 10.2337/dc14-2472. Epub 2015 Jul 7.</citation>
    <PMID>26153273</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <results_first_submitted>January 28, 2016</results_first_submitted>
  <results_first_submitted_qc>February 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2016</results_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>formoterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy subjects and Type 1 Diabetics were recruited to participate in the study. Subjects in either arm were randomized to receive a placebo or the study drug: Formoterol in either the first or second visit.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control: Placebo</title>
          <description>Healthy volunteers that received Placebo first, the Formoterol.</description>
        </group>
        <group group_id="P2">
          <title>Control: Formoterol</title>
          <description>Healthy volunteers that received Formoterol first, then Placebo.</description>
        </group>
        <group group_id="P3">
          <title>Type 1 Diabetics: Placebo</title>
          <description>Type 1 Diabetics that received Placebo first, then Formoterol.</description>
        </group>
        <group group_id="P4">
          <title>Type 1 Diabetics: Formoterol</title>
          <description>Type 1 Diabetics that received Formoterol first, then Placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cross-over at Second Visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
Formoterol: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
Placebo: Participants in both arms received placebo on 1 of the 2 visits.</description>
        </group>
        <group group_id="B2">
          <title>Type 1 Diabetics</title>
          <description>The active group were participants with type 1 diabetes.
Formoterol: Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
Placebo: Participants in both arms received placebo on 1 of the 2 visits.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="8"/>
                    <measurement group_id="B2" value="31" spread="11"/>
                    <measurement group_id="B3" value="33.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI, kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="2.1"/>
                    <measurement group_id="B2" value="25.8" spread="2.9"/>
                    <measurement group_id="B3" value="24.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="12.9"/>
                    <measurement group_id="B2" value="70.2" spread="10.6"/>
                    <measurement group_id="B3" value="70.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (%)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="2.6"/>
                    <measurement group_id="B2" value="6.8" spread="2.6"/>
                    <measurement group_id="B3" value="6.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (mmol/mol)</title>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="2.6"/>
                    <measurement group_id="B2" value="51.3" spread="8.5"/>
                    <measurement group_id="B3" value="43.5" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucagon (pg/mL)</title>
        <description>Glucagon levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages.</description>
        <time_frame>up to 120 minutes</time_frame>
        <population>Results are pooled at the arm level and split by placebo and control regardless of randomization order.</population>
        <group_list>
          <group group_id="O1">
            <title>Control: Placebo</title>
            <description>Healthy volunteers that received Placebo on the first or second visit.</description>
          </group>
          <group group_id="O2">
            <title>Control: Formoterol</title>
            <description>Healthy volunteers that received Formoterol on the first or second visit.</description>
          </group>
          <group group_id="O3">
            <title>Type 1 Diabetics: Placebo</title>
            <description>Type 1 Diabetics that received placebo on the first or second visit.</description>
          </group>
          <group group_id="O4">
            <title>Type 1 Diabetics: Formoterol</title>
            <description>Type 1 Diabetics that received Formoterol on the first or second visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon (pg/mL)</title>
          <description>Glucagon levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages.</description>
          <population>Results are pooled at the arm level and split by placebo and control regardless of randomization order.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="13"/>
                    <measurement group_id="O2" value="74" spread="11"/>
                    <measurement group_id="O3" value="53" spread="8"/>
                    <measurement group_id="O4" value="56" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" spread="11"/>
                    <measurement group_id="O2" value="58" spread="13"/>
                    <measurement group_id="O3" value="55" spread="10"/>
                    <measurement group_id="O4" value="54" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" spread="16"/>
                    <measurement group_id="O2" value="73" spread="18"/>
                    <measurement group_id="O3" value="43" spread="8"/>
                    <measurement group_id="O4" value="46" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Glucose Levels (Average)</title>
        <description>Blood glucose levels will be checked every 5 minutes during the 120 minute study session in order to maintain blood glucose levels in the normal and hypoglycemic range. Presented is the average of the collected values.</description>
        <time_frame>Up to 120 minutes</time_frame>
        <population>Subjects are pooled across randomized conditions in their respective study arms and reported overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Control: Placebo</title>
            <description>Healthy volunteers that received Placebo on the first or second visit.</description>
          </group>
          <group group_id="O2">
            <title>Control: Formoterol</title>
            <description>Healthy volunteers that received Formoterol on the first or second visit.</description>
          </group>
          <group group_id="O3">
            <title>Type 1 Diabetics: Placebo</title>
            <description>Type 1 Diabetics that received placebo on the first or second visit.</description>
          </group>
          <group group_id="O4">
            <title>Type 1 Diabetics: Formoterol</title>
            <description>Type 1 Diabetics that received Formoterol on the first or second visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Levels (Average)</title>
          <description>Blood glucose levels will be checked every 5 minutes during the 120 minute study session in order to maintain blood glucose levels in the normal and hypoglycemic range. Presented is the average of the collected values.</description>
          <population>Subjects are pooled across randomized conditions in their respective study arms and reported overall.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.38" spread="3.45"/>
                    <measurement group_id="O2" value="58.39" spread="2.40"/>
                    <measurement group_id="O3" value="53.21" spread="2.57"/>
                    <measurement group_id="O4" value="55.43" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Epinephrine (pg/mL)</title>
        <description>Epinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages</description>
        <time_frame>up to 120 minutes</time_frame>
        <population>Results are pooled at the arm level and split by placebo and control regardless of randomization order.</population>
        <group_list>
          <group group_id="O1">
            <title>Control: Placebo</title>
            <description>Healthy volunteers that received Placebo on the first or second visit.</description>
          </group>
          <group group_id="O2">
            <title>Control: Formoterol</title>
            <description>Healthy volunteers that received Formoterol on the first or second visit.</description>
          </group>
          <group group_id="O3">
            <title>Type 1 Diabetics: Placebo</title>
            <description>Type 1 Diabetics that received placebo on the first or second visit.</description>
          </group>
          <group group_id="O4">
            <title>Type 1 Diabetics: Formoterol</title>
            <description>Type 1 Diabetics that received Formoterol on the first or second visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Epinephrine (pg/mL)</title>
          <description>Epinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages</description>
          <population>Results are pooled at the arm level and split by placebo and control regardless of randomization order.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="4"/>
                    <measurement group_id="O2" value="16" spread="5"/>
                    <measurement group_id="O3" value="18" spread="4"/>
                    <measurement group_id="O4" value="17" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="3"/>
                    <measurement group_id="O2" value="12" spread="4"/>
                    <measurement group_id="O3" value="21" spread="5"/>
                    <measurement group_id="O4" value="13" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="15"/>
                    <measurement group_id="O2" value="55" spread="22"/>
                    <measurement group_id="O3" value="44" spread="15"/>
                    <measurement group_id="O4" value="19" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Norepinephrine (pg/mL)</title>
        <description>Norepinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages</description>
        <time_frame>up to 120 minutes</time_frame>
        <population>Results are pooled at the arm level and split by placebo and control regardless of randomization order.</population>
        <group_list>
          <group group_id="O1">
            <title>Control: Placebo</title>
            <description>Healthy volunteers that received Placebo on the first or second visit.</description>
          </group>
          <group group_id="O2">
            <title>Control: Formoterol</title>
            <description>Healthy volunteers that received Formoterol on the first or second visit.</description>
          </group>
          <group group_id="O3">
            <title>Type 1 Diabetics: Placebo</title>
            <description>Type 1 Diabetics that received placebo on the first or second visit.</description>
          </group>
          <group group_id="O4">
            <title>Type 1 Diabetics: Formoterol</title>
            <description>Type 1 Diabetics that received Formoterol on the first or second visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Norepinephrine (pg/mL)</title>
          <description>Norepinephrine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with inhaled formoterol. These levels will be checked every 20 minutes during the 120 minute study session. Results are presented at the Basal, Euglycemia (30 minutes) and Hypoglycemia (105-120 minutes) stages</description>
          <population>Results are pooled at the arm level and split by placebo and control regardless of randomization order.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" spread="37"/>
                    <measurement group_id="O2" value="192" spread="24"/>
                    <measurement group_id="O3" value="180" spread="28"/>
                    <measurement group_id="O4" value="133" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Euglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" spread="31"/>
                    <measurement group_id="O2" value="273" spread="22"/>
                    <measurement group_id="O3" value="226" spread="31"/>
                    <measurement group_id="O4" value="211" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="21"/>
                    <measurement group_id="O2" value="181" spread="14"/>
                    <measurement group_id="O3" value="241" spread="30"/>
                    <measurement group_id="O4" value="190" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported by the study arm and randomized visit order.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control: Placebo</title>
          <description>Healthy volunteers that received Placebo on the first visit.</description>
        </group>
        <group group_id="E2">
          <title>Control: Formoterol</title>
          <description>Healthy volunteers that received Formoterol on the first visit.</description>
        </group>
        <group group_id="E3">
          <title>Type 1 Diabetics: Placebo</title>
          <description>Type 1 Diabetics that received placebo on the first visit.</description>
        </group>
        <group group_id="E4">
          <title>Type 1 Diabetics: Formoterol</title>
          <description>Type 1 Diabetics that received Formoterol on the first visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Shakiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Light Headedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Sherwin, MD</name_or_title>
      <organization>Department of Internal Medicine and Endocrinology, Yale University School of Medicine, New Haven, CT</organization>
      <phone>(203) 785-3482</phone>
      <email>robert.sherwin@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

